Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 15, 2019 and accepted by EDGAR at May 15, 2019, 16:16 ET.
Management's discussion and analysis
As filed, 24,568 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as amended by Form 10-K/A. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed above in “Cautionary Statement Regarding Forward-Looking Statements” and elsewhere in this Form 10-Q.
Executive Summary
We develop, manufacture, and market regenerative medicine products and medical devices for domestic and international markets. Our products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants, and instrumentation for the treatment of spinal disease. We promote our products in the United States largely through independent distributors and stocking agents, augmented by direct employees.
During the first quarter of 2018, we effected a significant restructuring pursuant to which we converted an aggregate of $71.9 million of aggregate principal amount of debt into equity by issuing an aggregate of 10,590,954 shares of our stock, in cancellation thereof, issued an additional 945,819 shares of our common stock in a private placement for an aggregate purchase price of $6.8 million, completed a 1-for-12 reverse split of our common stock after the close of business on February 13, 2018, and replaced our entire Board of Directors. We completed this restructuring during the second quarter of 2018 with a common stock stockholder rights offering, which expired on June 18, 2018, and resulted in the issuance of an additional 129 shares of common stock. Upon completion of this restructuring and as of March 31, 2019, two funds affiliated with OrbiMed, which held a significant portion of our converted indebtedness and continue to hold all of our currently outstanding debt, own approximately 70% of our outstanding common stock. Because of this significant ownership, we are a “controlled company” within the meaning of NYSE American corporate governance standards.
During 2018 and continuing through the first quarter of 2019, we experienced reduced revenues due primarily to continued softness in our hardware product line for both domestic and international sales. As of March 31, 2019, our cash and cash equivalents were $7.1 million. On March 29, 2019, we entered into a Second Amended and Restated Credit Agreement, which amended and restated our Prior Credit Agreement, revised certain covenants and increased our credit availability by $10.0 million, resulting in total availability of $12.2 million as of March 31, 2019.
On April 4, 2019, we received a letter from the NYSE American LLC (the “Exchange”) notifying us that we are not in compliance with the Exchange’s continued listing standards relating to stockholders’ equity. Specifically, we are not in compliance with Section 1003(a)(i) of the Company Guide with stockholders’ equity of less than $2.0 million and net losses in two of its three most recent fiscal years, Section 1003(a)(ii) with stockholders’ equity of less than $4.0 million and net losses in three of its four most recent fiscal years, and Section 1003(a)(iii) with stockholders’ equity of less than $6.0 million and net losses in its five most recent fiscal years. Therefore, we became subject to the procedures and requirements of Section 1009 of the Company Guide. On May 3, 2019, we submitted a plan of compliance to the Exchange addressing how we intend to regain compliance with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) or meet the exemption in Section 1003(a) of the Company Guide by October 4, 2020. Our common stock will continue to trade on the Exchange under the symbol “XTNT,” with the added designation of “.BC” to indicate that we are not in compliance with the Exchange’s continued listing standards.
Results of Operations
Comparison of Three Months Ended March 31, 2019 and March 31, 2018
Revenue
Total revenue for the three months ended March 31, 2019 was $16.7 million, which represents a decrease of 7% compared to $17.9 million in the same quarter of the prior year. The decline is primarily due to continued softness in the company’s hardware product line for both domestic and international sales.
Cost of Sales
Cost of sales consists primarily of manufacturing and product purchase costs as well as depreciation of surgical trays. Cost of sales also includes reserves for estimated excess inventory, inventory on consignment that may be missing and not returned, and reserves for estimated missing and damaged consigned surgical instruments. Cost of sales increased by 3.7%, or $0.2 million, to $5.9 million for the three months ended March 31, 2019 from $5.7 million for the three months ended March 31, 2018. As a percentage of revenue, cost of sales increased to 35.4% for the three months ended March 31, 2019 versus 31.8% in the year-ago period. The percentage increase was attributed primarily to inventory reserving and manufacturing overhead absorption.
Operating Expenses
Operating expenses include general and administrative expenses, sales and marketing expenses, research and development expenses, depreciation and amortization, impairment of goodwill and intangible assets, restructuring expenses, and compensation costs, including incentive compensation. Operating expenses decreased 17.3%, or $2.4 million for the three months ended March 31, 2019, compared to the three months ended March 31, 2018. As a percent of total revenue, operating expenses were 68.6% in the three months ended March 31, 2019, compared to 77.4% in the comparable period in the prior year. The decrease in operating expenses is primarily due to the reduction in sales and marketing expenses of $1.6 million due primarily to lower sales commissions and travel expenses. In addition, amortization expense was lower by $0.8 million because of the impairment of intangibles assets that occurred in the fourth quarter of 2018.
General and Administrative
General and administrative expenses consist principally of personnel costs for corporate employees, cash-based and stock-based compensation related costs, and corporate expenses for legal, accounting, and other professional fees, as well as occupancy costs. General and administrative expenses increased 38.7%, or $1.2 million, to $4.2 million for the three months ended March 31, 2019, compared to the same period of 2018. The increase is primarily attributable to settlement expenses totaling $0.5 million, increased professional fees of $0.5 million and increased legal expenses of $0.2 million incurred during the three months ended March 31, 2019 compared to the same prior year period.
Sales and Marketing
Sales and marketing expenses consist primarily of sales commissions, personnel costs for sales and marketing employees, costs for trade shows, sales conventions and meetings, travel expenses, advertising, and other sales and marketing related costs. Sales and marketing expenses decreased 19.2%, or $1.6 million, to $6.7 million for the three months ended March 31, 2019, compared to $8.3 million for the same period of 2018. As a percentage of revenue, sales and marketing expenses decreased to 40.3% in the three months ended March 31, 2019 from 46.6% in the comparable period the prior year. These decreases were primarily due to lower travel expenses, headcount, decreased commissions attributable to decreased revenue, and the impact from changes made to the commission rate structure under certain distribution agreements.
Research and Development
Research and development expenses consist primarily of internal costs for the development of new technologies and processes. Research and development expenses decreased 36.7%, or $0.2 million, from $0.4 million for the three months ended March 31, 2018 to $0.2 million for the same period of 2019. This decrease is primarily due to a reduction in headcount as compared to the prior year period. During the first quarter of 2019, management decided to defer a portion of its new product development spend into the third and fourth quarters of 2019.
Depreciation and Amortization
Depreciation and amortization expense consist of depreciation and amortization of long-lived intangible assets, patents, leasehold improvements, and equipment. Depreciation and amortization expense decreased $0.8 million to $0.2 million for the three months ended March 31, 2019, from $1.0 million for the same period in 2018 primarily due to the impairment of the intangible assets in the fourth quarter of 2018.
Restructuring Expenses
Restructuring expenses were zero for the three months ended March 31, 2019 and $0.7 million for the three months ended March 31, 2018. Restructuring costs for the three months ended March 31, 2018 related to our recapitalization and debt restructuring.
Non-cash Consulting Expense
Non-cash consulting expense consists of non-cash expense associated with granting restricted stock to directors and consultants. Non-cash consulting expense decreased $0.2 million to $0.1 million for the three months ended March 31, 2019 from $0.4 million for the same period in the prior year primarily as a result of the grant of restricted stock to our non-employee directors during the three months ended March 31, 2018 which did not recur during the same period of this year.
Interest Expense
Interest expense is related to interest incurred from our debt instruments. Interest expense was $2.0 million for the three months ended March 31, 2019 compared to $3.5 million for the three months ended March 31, 2018. The decrease in interest expense is due to the Twenty-Fifth Amendment to the Prior Credit Agreement, resulting in lower effective interest rates on our outstanding debt during the three months ended March 31, 2019 compared to the prior year period.
Change in Warrant Derivative Liability
For the three months ended March 31, 2019, we recorded a loss in our non-cash warrant derivative liability of $15 thousand, which was primarily driven by the change in the closing price of our common stock at March 31, 2019 and 2018, respectively. This liability is associated with the issuance of warrants as part of our prior convertible debt financing, our 2010 financing, and our 2014 equity financing, which contain certain provisions requiring us to record a change in the fair value of the warrant derivative liability from period to period.
Liquidity and Capital Resources
Working Capital
Since our inception, we have financed our operations through operating cash flows, the private placement of equity securities and convertible debt, an equity credit facility, a debt facility, a common stock rights offering, and other debt transactions.
| March 31, 2019 | December 31, 2018 | |
|---|---|---|
| Cash and cash equivalents | $7,097 | $6,797 |
| Accounts receivable, net | 9,493 | 9,990 |
| Inventories, net | 16,526 | 17,301 |
| Total current assets | 33,580 | 34,677 |
| Accounts payable | 6,036 | 6,465 |
| Accrued liabilities | 4,429 | 5,150 |
| Total current liabilities | 11,252 | 12,051 |
| Total working capital | 22,328 | 22,626 |
| Long-term debt, less issuance costs | 72,657 | 77,939 |
Long-term debt, less issuance costs, consist of long-term debt due to the lenders under our Second Amended and Restated Credit Agreement as of March 31, 2019 and under our Prior Credit Agreement as of December 31, 2018. The execution of the Second Amended and Restated Credit Agreement during the first quarter of 2019 and the changes to our credit facility reflected therein, including the interest rate relief and extended maturity, along with the additional availability, were determined to be and accounted for as a debt extinguishment under U.S. generally accepted accounting principles (“GAAP”), resulting in the write-off of the original loan and associated issuance costs. The present value of the new loan was determined to be $72.7 million as of March 31, 2019 with the Company recording an increase to additional paid-in capital of $7.3 million. Because of the related party affiliation between the Company and our credit facility lenders, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our condensed consolidated statements of operations as a gain on extinguishment. While the fair value of our long-term debt, less issuance costs, was $72.7 million as of March 31, 2019 under GAAP, the Company still owes a principal balance of $50.7 million plus accrued PIK interest of $28.8 million as of March 31, 2019. Assuming no debt payments are made, our long-term debt, less issuance costs line item will continue to increase until the loan’s March 31, 2021 maturity date. See Note 6, “Debt” to the condensed consolidated financial statements.
Cash Flows
Net cash provided by operating activities for the first three months of 2019 was $0.5 million driven primarily from improvement in operating activities of $0.6 million, partially offset by changes in operating assets and liabilities of $0.1 million. For the comparable period of 2018, net cash provided by operating activities was $0.2 million.
Net cash used in investing activities for the first three months of 2019 and 2018 was $0.1 million and $0.1 million, respectively, primarily representing purchases of property and equipment.
Net cash used in financing activities was $0.1 million compared to net cash provided by financing activities of $3.2 million for the first three months of 2019 and 2018, respectively. The net cash provided by the prior year period was due to proceeds from a private placement, partially offset by costs associated therewith and our debt conversion.
Credit Facility
On March 29, 2019, we entered into the Second Amended and Restated Credit Agreement with the Investors, which amended and restated the Prior Credit Agreement dated as of July 27, 2015, among the parties thereto, and as subsequently amended through the Twenty-Fifth Amendment to the Prior Credit Agreement.
The Second Amended and Restated Credit Agreement amended the Prior Credit Agreement to provide that we may request term loans with the Investors in an amount equal to the remaining commitment for additional delayed draw loans, which was approximately $2.2 million as of the date of the Second Amended and Restated Credit Agreement, and request additional term loans in an aggregate amount of up to $10.0 million, the amount of each loan draw to be subject to our production of a thirteen-week cash flow forecast that is approved by the Investors and which shows a projected cash balance for the following two-week period of less than $1.5 million, as well as the satisfaction (or waiver in writing by each Investor) of conditions precedent, including closing certificate, delivery of budget, and other satisfactory documents. In addition, the Second Amended and Restated Credit Agreement provides that (i) no interest will accrue on the Loans under the Second Amended and Restated Credit Agreement from and after January 1, 2019, until March 31, 2020; (ii) beginning April 1, 2020, through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the Loans under the Credit Agreement at a rate per annum equal to the sum of (a) 10.00% plus (b) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 2.3125%; (iii) the maturity date of the Loans is March 31, 2021; (iv) the Consolidated Senior Leverage Ratio and Consolidated EBITDA (as such terms were defined in the Prior Credit Agreement) financial covenants were deleted and a new Revenue Base (as such term is defined in the Second Amended and Restated Credit Agreement) financial covenant was added; and (v) the key person event default provision was revised to refer specifically to certain recently-hired executive officers of the Company. Under the terms of the Prior Credit Agreement, we were required to comply with a minimum liquidity covenant, a consolidated leverage ratio covenant, and a minimum consolidated EBITDA covenant. We were in compliance with all covenants under the Second Amended and Restated Credit Agreement as of March 31, 2019 and under the Prior Credit Agreement as of December 31, 2018. As of March 31, 2019, there was $12.2 million in unused availability under the Second Amended and Restated Credit Agreement.
Cash Requirements
We believe that our March 31, 2019, cash and cash equivalents of $7.1 million, together with the availability of $12.2 million under our new Second Amended and Restated Credit Agreement, will be sufficient to meet our anticipated cash requirements through the end of March 2020. However, we may require additional funds to fund our future operations and business strategy. Accordingly, there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable. We may seek to raise additional funds through various sources, such as equity and debt financings, additional debt restructurings or refinancings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate.
To the extent that we raise additional capital through the sale of equity or convertible debt securities or the restructuring or refinancing of our debt, the interests of our current stockholders may be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Prior to raising additional equity or debt financing, we must obtain the consent of the Investors, and no assurance can be provided that the Investors would provide such consent, which could limit our ability to raise additional financing.
Off Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures, or capital resources that are material to an investor in our shares.
Recent Accounting Pronouncements
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use (“ROU”) asset and lease liability on their balance sheet for all leases with terms beyond 12 months. The new standard also requires enhanced disclosures that will provide more transparency and information to financial statement users about our lease portfolio. The distinction between operating and finance leases will continue to exist under the new standard. Additionally, the recognition and measurement of operating and finance lease expenses and cash flows will not change significantly from current treatment. For finance leases, lessees will continue to recognize interest expense on the lease liability using the effective yield method, while the right-of-use asset will be amortized on a straight-line basis. For operating leases, expense will be recognized on a straight-line basis, consistent with the previous standard. See Note 10, “Commitments and Contingencies,” to the condensed consolidated financial statements
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments–Credit losses: Measurement of Credit Losses on Financial Instruments, which amends certain provisions of ASC 326, Financial Instruments–Credit Loss. The ASU changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The ASU is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods, and will be applied as a cumulative effect adjustment to retained earnings as of the beginning of the first reporting period for which the guidance is effective. We currently do not expect that the adoption of these provisions will have a material effect on our consolidated financial statements.
In June 2018, the FASB issued ASU No. 2018-07, Stock Compensation (Topic 718), which amends the current standard. Specifically, the new standard expands the scope of Topic 718 to include share-based payment awards to non-employees. Additionally, the ASU expands and amends the current standard to include and realign consistent with the changes to revenue standard Topic 606. Management expects that the adoption of this new standard will qualitatively impact the Company’s financial reporting. See further information in Note 8, “Stock-Based Compensation.”
In August 2018, the FASB issued ASU No. 2018-15, Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40), to simplify the accounting for goodwill impairment. The update removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The ASU is effective for annual reporting periods beginning after December 15, 2019, but early adoption is permitted. We are currently evaluating this update to determine the full impact of its adoption but do not expect this accounting standards update to have a material impact on our consolidated financial position, results of operations, or cash flows.
Critical Accounting Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.
There have been no changes in our critical accounting estimates for the three months ended March 31, 2019 as compared to the critical accounting estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Controls and procedures
As filed, 1,705 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive and financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of March 31, 2019. Based upon that evaluation, our principal executive and financial officer concluded that as of March 31, 2019, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, other than hiring a new Interim Chief Financial Officer in February 2019, the resignation of the Company’s Interim Chief Executive Officer in March 2019 and the assumption of the principal executive officer role by the Interim Chief Financial Officer upon resignation of the Interim Chief Executive Officer.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $5.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-01-01 to 2019-03-31 | $10.8m | us-gaap:GrossProfit |
| Research and development | 3 months2019-01-01 to 2019-03-31 | $262.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | −$668.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-01-01 to 2019-03-31 | $2.0m | us-gaap:InterestExpense |
| Income tax | 3 months2019-01-01 to 2019-03-31 | −$23.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-01-01 to 2019-03-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-01-01 to 2019-03-31 | 13,170,721 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | $490.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-03-31 | $7.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $33.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $47.1m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $11.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $86.2m | us-gaap:Liabilities |
| Long-term debt | At period end2019-03-31 | $72.7m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-03-31 | −$39.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-19-007404. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.